Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK119 + AK104 in Advanced Solid Tumors
CTR20222394Phase 2Terminated
- Sponsor
- Akeso, Inc.
- Start
- Sep 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ambuzutinib, cadonilimab in Nonhematologic neoplasms, sponsored by Akeso, Inc.. Started Sep 2022; status: terminated.
02
Drugs
ambuzutinibcadonilimab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20222394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222394.